The neuropsychiatric sector is undergoing a structural paradigm
shift toward interventional psychiatry, rapid-acting, highly durable, in-office
therapies that treat severe illness at the root mechanics.
At the B. Riley Securities' Mind, Muscle & Vision Summit in Boston,
clinical and commercial leaders gathered for our panel Commercializing the Next
Wave of Novel Neuropsychiatric Drugs moderated by Madison El-Saadi, Ph.D.,
Equity Research Analyst at B. Riley Securities.
The panel featured:
• Steve Levine, M.D., Chief Patient Officer at Compass
Pathways (NASDAQ: CMPS)
• Dan Reuvers, President & Chief Executive Officer at
Neuronetics (NASDAQ: STIM)
• Cory Anderson, Executive Vice President & General
Manager at Greenbrook at Neuronetics (NASDAQ: STIM)
Here are our four key
takeaways from the discussion:
Psychiatry's
"Cardiology Moment"
Psychiatry is pivoting away from chronic medical management toward high-value,
procedure-based interventions. Next-generation pipeline assets represent the
high-growth expansion of this market, with payer coverage and physician
adoption coalescing around durable, in-office care models that deliver
multi-month remission.
The Distribution
Bottleneck Is Already Solved
Specialized outpatient clinic networks spanning dozens of states are already
fully operational. Novel pipeline therapies can be plugged directly into
existing interventional clinic footprints with minimal incremental capital
expenditure.
High-Margin
"Buy-and-Bill" Economics
For certain approved therapies, unbundling administration and monitoring
services from the drug cost creates an oncology-style Buy-and-Bill economic
structure, reimbursed at Average Sales Price (ASP) plus a margin. This model
improves clinic-level unit economics and incentivizes provider adoption. While
TMS operates under fee-for-service reimbursement and ketamine remains largely
cash-pay, the commercial trajectory points toward broader adoption of
margin-accretive reimbursement frameworks as the category matures.
The Surface Has Barely
Been Scratched
According to industry estimates, over 4 million U.S. patients suffer from
Treatment-Resistant Depression (TRD), accounting for roughly 50% of total Major
Depressive Disorder direct healthcare spending, yet less than 3% of the
eligible population currently receives advanced interventional care. As
late-stage pipeline assets approach commercialization over the next 12 to 24
months, significant pent-up demand is waiting to be unlocked.
Follow us on LinkedIn for
additional insights and learn more about our upcoming events at brileysecurities.com/events.